The manipulation of genetically targeted neurons with light (optogenetics) continues to provide unprecedented avenues into studying the function of the mammalian brain. However, potential translation into the clinical arena faces a number of significant hurdles, foremost among them the need for insertion of optical fibers into the brain to deliver light to opsins expressed on neuronal membranes. In order to overcome these hardware-related problems, we have developed an alternative strategy for delivering light to opsins which does not involve fiber implants. Rather, the light is produced by a protein, luciferase, which oxidizes intravenously applied substrate, thereby emitting bioluminescence. In proof-ofprinciple studies employing a fusion protein of a light-generating luciferase to a light-sensing opsin (luminopsin), we showed that light emitted by Gaussia luciferase is indeed able to activate channelrhodopsin, allowing modulation of neuronal activity when expressed in cultured neurons. Here we assessed applicability of the concept in vivo in mice expressing luminopsins from viral vectors and from genetically engineered transgenes. The experiments demonstrate that intravenously applied substrate reaches neurons in the brain, causing the luciferase to produce bioluminescence which can be imaged in vivo, and that activation of channelrhodopsin by bioluminescence is sufficient to affect behavior. Further developments of such technology based on combining optogenetics with bioluminescence -i.e. combining lightsensing molecules with biologically produced light through luciferases -should bring optogenetics closer to clinical applications.
INTRODUCTION
Manipulating the activity of defined neuronal populations in the living organism is critical for understanding of how neural circuits process information, and, ultimately, for applying efficient therapies to numerous neurological and psychiatric disorders. The past several years have shown an exciting development of tools for probing neural circuits in vivo with light (optogenetics) or with chemical compounds (chemical genetics) 1 . These approaches make use of one genetically targeted component, typically a receptor or ion channel, and one externally administered component, such as a small molecule or light. In chemical genetic approaches, for example DREADDs, activation is mediated by a diffusible molecule that can be delivered by non-invasive systemic application. DREADDs are G-protein coupled receptors and thus pose restrictions on the neuronal populations that can be manipulated as well as on the time scales of manipulation 2 . Optogenetic actuators are attractive as they are independent of second messenger systems and thus can be employed more generally. In addition, the optogenetic principle is applicable not only to opsins (channels and pumps, such as channelrhodopsins [3] [4] [5] , halorhodopsins [6] [7] [8] or archaerhodopsin 9 ), but to a broader and rapidly expanding arsenal of tools for light-based cellular manipulation, such as plant phytochromes, cryptochromes, and light-oxygen-voltage (LOV) domain proteins for controlling protein localization, signaling pathways, and DNA recombination and transcription [10] [11] [12] . However, the hardware requirements for light delivery in vivo, i.e. chronically implanted fiber optics, poses significant limitations in experimental animals and even more so in potential clinical applications. First, in order to activate the same number of neurons in the human brain as in mice, the optical fibers will have to be scaled up in diameter, which leads to considerable neuronal damage along the path of the fiber. Second, inflammatory reactions to the foreign fiber material, especially during chronic insertion, can cause the tissue to become so opaque that the light cannot even reach 
Virus
Lentivirus vectors were made by transfecting 6 × 10 6 293FT cells with 5 μg of the vesicular stomatitis virus glycoprotein (VSVg) envelope encoding plasmid, 15 μg of the delta-8.9 packaging plasmid, and 20 μg of LMO plasmid using Lipofectamine. After 72 h, supernatant was harvested from three 10 cm culture plates, filtered at 0.45 μm, and pelleted by ultracentrifugation at 26,000 rpm for 2 h at 4°C. After resuspension, serially diluted lentivirus was used to transduce 293FT cells; 72 h later, labeled 293FT cells were counted to calculate the viral titer. Lentiviruses with titers ranging from 1 × 10 7 to 1 × 10 10 TU/ml were used in this study.
Mice
All experimental procedures were conducted in accordance with National Institutes of Health guidelines and reviewed by Duke University's Institutional Animal Care and Use Committee.
For virus injections mice at postnatal day 1 (P1) were anesthetized by hypothermia. Injections were made into the cortex through the translucent skull using a glass pipette attached to a Hamilton syringe. Sham-injected mice received PBS without virus. Mice were returned to their home cage until weaning at P21 -P28. Adult mice between P30 and P45 were used for imaging and behavioral experiments.
For injection of the luciferase substrate, coelenterazine (CTZ), mice were briefly anesthetized with isoflurane. CTZ of high purity (NanoLight™Technology, Pinetop, AZ) was injected into the retroorbital venous plexus, dispensing 50 µl per mouse with a 0.5 ml Insulin syringe, for a final concentration of 200 µM. In in vivo imaging experiments, mice were kept under continuous isoflurane anesthesia. In behavioral experiments, after recovery from anesthesia, mice were put in a chamber where they were allowed to move freely under video recordings.
Histology
Mice were killed by an overdose of isoflurane and transcardially perfused with sodium phosphate buffer (PBS), followed by 4% paraformaldehyde (PFA) in PBS. The brain was removed and postfixed in 4% PFA overnight, followed by 30% sucrose overnight. Brains were sliced into transverse or coronal sections on a freezing microtome at 40-50 μm, directly mounted onto glass slides, and cover-slipped using Fluormount-G (Electron Microscopy Sciences, Hatfield, PA). Widefield fluorescence microscopy images were acquired with an Olympus BX61 upright microscope using a 40x Olympus objective, a GFP filter cube (U-MWIB, Olympus), a high-resolution cooled CCD camera (CoolSNAP fx, Photometrics, Tucson, AZ) and acquisition software (ISee Imaging Systems, Raleigh, NC).
Bioluminescence imaging in vivo
Immediately after retroorbital injection of CTZ, mice were imaged using a Xenogen IVIS 100 system and Living Image 3.0 software (Caliper Life Sciences). Images were displayed as a pseudo-color photon count image. Where applicable, regions of interest were defined using an automatic intensity contour procedure to identify bioluminescent signals with intensities significantly greater than background. The sum of the photon counts in these regions was then calculated.
Fluorescence and bioluminescence imaging ex vivo
Hippocampal slices were prepared using conventional methods 22 . In brief, the mice were anesthetized with isoflurane and then decapitated. Their brains were removed and placed in cold artificial cerebrospinal fluid (ACSF), containing (in mM): 125 NaCl, 2. (Fig. 3, right (Fig. 3, left) . C of the contral ior.
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